Jagsonpal Pharmaceuticals has reported a 23.1% YoY surge in Q1 FY26 revenue to Rs. 75.6 crore powered by sustained performance across its key brands.

The company’s focused brand-building strategy continued to yield results, enhancing market presence.

Gross margins improved by 80 bps to 64.4%, backed by strong brand equity and disciplined cost management. Operating EBITDA grew 24.1% to Rs. 15.7 crore, with margins at 20.8%. Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution.

With addition of 15.3 crore of free cash during the quarter, cash position stood Rs. 160.9 crore as of June 30, 2025 giving ample room to invest in future growth.

Commenting on the performance for the quarter, Manish Gupta, Managing Director and CEO, Jagsonpal Pharmaceuticals Limited said, “We have started FY 26 on a strong note with growth across all parameters. While our revenue grew 23.1% to Rs. 75.6 crore, operating EBITDA was at Rs. 15.7 crore, up by 24.1%. The continued scale up is an outcome of our disciplined and effective execution of our strategy. Net profit for the quarter more than doubled to Rs. 10.8 crore, with addition of another Rs. 15.3 crore of free cash, which stood at Rs. 160.9 crore as on 30th June 2025. We further strengthened our position to #7 in the Gynae CVM rankings, reinforcing our leadership in the category. We expect the growth momentum to continue as we deepen our presence in the domestic pharmaceutical market coupled with prudent use of free cash to look for a strategically suitable inorganic opportunity."